PremiumRatingsZimmer Biomet Holdings: Strategic Positioning and Cautious Growth Outlook with Hold Rating Zimmer Biomet Holdings: Strategic Initiatives and Execution Risks Justify Hold Rating Zimmer Biomet Holdings: Balancing Optimism with Caution Amid Strategic Growth and Market Challenges PremiumCompany AnnouncementsZimmer Biomet Announces Leadership Changes in 2025 Zimmer Biomet price target lowered to $113 from $118 at Truist Zimmer Biomet price target lowered to $112 from $118 at Barclays PremiumThe FlyZimmer Biomet price target lowered to $130 from $138 at Baird Zimmer Biomet Holdings: Hold Rating Amid Strategic Initiatives and Execution Uncertainties Zimmer Biomet Reports Strong 2024 Financial Performance 
